Alternatives to Degron Therapeutics
Degron Therapeutics is a Biotechnology tool: clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
The 20 closest Biotechnology companies to Degron Therapeutics
Moderna2.5 out of 5 (2)Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
BiotechnologymRNA TechnologyUpdated 9 Jul 2026
Pixelgen TechnologiesNot ratedA life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
BiotechnologyLife SciencesUpdated 24 Aug 2026
Epicrispr BiotechnologiesNot ratedEpicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
BiotechnologyTherapeuticsUpdated 18 Aug 2026
AdcendoNot ratedDeveloping first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
BiotechnologyPharmaceuticalsUpdated 5 Aug 2026
EnteromeNot ratedClinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
BiotechnologyDrug DiscoveryUpdated 1 May 2026
LifeMine Therapeutics Inc.Not ratedClinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.
BiotechnologyDrug DiscoveryUpdated 8 Aug 2026
CellCentricNot ratedA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
BiotechnologyPharmaceuticalsUpdated 8 May 2026
InfinimmuneNot ratedDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
BiotechnologyPharmaceuticalsUpdated 19 Aug 2026
MironidNot ratedBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
BiotechnologyPharmaceuticalsUpdated 8 Aug 2026
FreenomeNot ratedFreenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
BiotechnologyHealthcareUpdated 22 Sept 2026
4D PathNot ratedPersonalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.
BiotechnologyHealthTechUpdated 6 May 2026
CelerionNot ratedA global leader in clinical pharmacology and bioanalytical sciences.
BiotechnologyPharmaceuticalsUpdated 1 May 2026
Spark TherapeuticsNot ratedA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
BiotechnologyGene TherapyUpdated 12 Aug 2026
ImmunoScapeNot ratedDeveloping novel immunotherapies and diagnostics for cancer.
BiotechnologyCancerUpdated 24 Jun 2026
Janux TherapeuticsNot ratedA clinical-stage biopharmaceutical company developing novel immunotherapies.
BiotechnologyPharmaceuticalsUpdated 30 Aug 2026
Rocket PharmaceuticalsNot ratedA biotechnology company developing genetic therapies for rare disorders.
BiotechnologyPharmaceuticalsUpdated 29 Apr 2026
KaliVir Immunotherapeutics, Inc.5.0 out of 5 (1)Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.
BiotechnologyHealthUpdated 25 Aug 2026- LŌLōkahi TherapeuticsNot rated
A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.
BiotechnologyPharmaceuticalsUpdated 6 May 2026
Verve TherapeuticsNot ratedDeveloping gene editing therapies to lower cholesterol.
BiotechnologyGene TherapyUpdated 13 Sept 2026- EAEarendil LabsNot rated
Earendil Labs is an AI biotechnology company focused on leveraging artificial intelligence for drug discovery and development of next-generation biologics.
BiotechnologyArtificial IntelligenceUpdated 23 Aug 2026
Showing the 20 closest matches. See the rest on the Degron Therapeutics profile.